3C-P
Psychedelic drug
From Wikipedia, the free encyclopedia
3C-P, also known as 4-propoxy-3,5-dimethoxyamphetamine or as α-methylproscaline (3C-proscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA).[2][4] It is the amphetamine (3C) analogue of proscaline.[2][4]
| |
 | |
| Clinical data | |
|---|---|
| Other names | 4-Propoxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-propoxyamphetamine; α-Methylproscaline; 3C-Proscaline |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Duration of action | Unknown[2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO3 |
| Molar mass | 253.342 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Use and effects
3C-P has been reported to have a dose range of 20 to 40 mg orally, with a typical dose estimate of 30 mg, based on informal anecdotal reports.[1] Although 3C-P produces hallucinogenic effects, very little is known about its effects.[5]
Interactions
Pharmacology
Pharmacodynamics
3C-P acts as a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A receptor.[4][6] It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[5][1][6]
Chemistry
History
3C-P was first described in the scientific literature by Otakar Leminger by 1972.[8][9] Alexander Shulgin mentioned it in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved)[2] and Daniel Trachsel synthesized it in 2002, but neither of them reported its properties or effects in humans.[7][3][10] The drug has been sold online as a designer drug and was first detected in September 2013 in Finland.[11][12]
Society and culture
Legal status
Canada
3C-P is a controlled substance in Canada under amphetamine blanket-ban language.[13]
United States
3C-P is not an explicitly controlled substance in the United States, although it would most likely be considered a controlled substance under the Federal Analogue Act as an analogue of 2C-P.[14]